Healthcare
Live Price
Offline$14.55
+2.25% today
1Y Change
-25.10%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Surgery Partners, Inc. (SGRY) is a Healthcare stock with a market cap of $1.85B and listed on NASDAQ. The stock last traded around $14.55 and down 25.1% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +6.2%, EPS growth of +54.1%, a dividend yield of 0.0%. What stands out right now is revenue +6.2%, EPS +54.1%, free cash flow -6.7% with operating margin 11.8% and ROIC 4.2%. Valuation is more restrained than many high-expectation growth names at price/sales 0.6. Stock Foundry combines SGRY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SGRY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SGRY Max Drawdown
-51.80%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SGRY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.2B
-12.4% YoY
FY Net Income
-$70.9M
-29.9% YoY
Free Cash Flow
$29.5M
-62.3% YoY
Revenue Growth
+6.2%
EPS Growth
+54.1%
Gross Margin
23.1%
Net Margin
-2.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.3B | 3.1B | 2.7B | 2.5B | 2.2B |
| Gross Profit | 765M | 746M | 648M | 575M | 491M |
| Operating Income | 390M | 349M | 328M | 345M | 302M |
| EBITDA | 566M | 501M | 446M | 460M | 401M |
| Net Income | -78M | -168M | -12M | -55M | -71M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 240M | 270M | 196M | 283M | 390M |
| Total Assets | 8.2B | 7.9B | 6.9B | 6.7B | 6.1B |
| Total Liabilities | 4.7B | 4.3B | 3.5B | 3.4B | 3.8B |
| Shareholder Equity | 1.7B | 1.8B | 2.0B | 2.0B | 1.1B |
| Total Debt | 4.0B | 3.7B | 3.1B | 2.9B | 3.3B |
| Net Debt | 3.8B | 3.4B | 2.9B | 2.6B | 2.9B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
87M
-45.2% YoY
Capital Expenditures
58M
+28.5% YoY
Free Cash Flow
30M
-62.3% YoY
Key ratios
Gross Margin
23.1%
Operating Margin
11.8%
Net Margin
-2.4%
ROE
-4.5%
Debt / Equity
2.35x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.